ESMO BC 2023

ESMO BC 2023
May 11-13, 2023
Berlin, Germany

European Society for Medical Oncology Breast Cancer 2023.

Explore more information for Gilead Oncology therapies
Results (2)

Safety Outcomes by UGT1A1 Status in the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan in HR+/HER2– Metastatic Breast Cancer

Relationship of Diarrhea and Neutropenia Events with Outcomes in Patients with Metastatic Triple-Negative Breast Cancer Treated with Sacituzumab Govitecan: Post Hoc Analysis from the Phase 3 ASCENT Study